Delving into the Latest Updates on Hefei TG ImmunoPharma Co., Ltd with Synapse

Overview

Tags

Neoplasms

Digestive System Disorders

Skin and Musculoskeletal Diseases

Monoclonal antibody

Bispecific T-cell Engager (BiTE)

T cell engagers (TCE)

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	20
Immune System Diseases	5
Endocrinology and Metabolic Disease	5
Infectious Diseases	4

Top 5 Drug Type	Count

Monoclonal antibody	10
T cell engagers (TCE)	3
Bispecific antibody	2
NK cell engagers (NKCE)	1
Cytokines	1

Top 5 Target	Count

CD3(T cell surface glycoprotein CD3)	3
CD112R(Transmembrane protein PVRIG)	2
NCR3LG1(natural killer cell cytotoxicity receptor 3 ligand 1)	2
IL2RA x PD-1	1
CD94(killer cell lectin like receptor D1)	1

主要目的：●确定TGI-5注射液单药治疗在局部晚期/转移性实体瘤受试者中的MTD/OBD。●评价TGI-5注射液单药治疗在局部晚期/转移性实体瘤受试者中的安全性特征。次要目的：●评价TGI-5注射液单药治疗在局部晚期/转移性实体瘤受试者中的PK特征。●评价TGI-5注射液单药治疗在局部晚期/转移性实体瘤受试者中的初步抗肿瘤活性。●表征TGI 5注射液单药治疗在局部晚期/转移性实体瘤受试者中的免疫原性。探索性目的：●评价肿瘤组织中的CD155表达，并探索其与TGI-5注射液抗肿瘤活性和安全性之间的潜在关系。●探索剂量和PK暴露量与效应（包括有效性和/或安全性）之间的关系。

[Translation]

Primary objectives: ● Determine the MTD/OBD of TGI-5 injection monotherapy in subjects with locally advanced/metastatic solid tumors. ● Evaluate the safety profile of TGI-5 injection monotherapy in subjects with locally advanced/metastatic solid tumors. Secondary objectives: ● Evaluate the PK characteristics of TGI-5 injection monotherapy in subjects with locally advanced/metastatic solid tumors. ● Evaluate the preliminary anti-tumor activity of TGI-5 injection monotherapy in subjects with locally advanced/metastatic solid tumors. ● Characterize the immunogenicity of TGI 5 injection monotherapy in subjects with locally advanced/metastatic solid tumors. Exploratory objectives: ● Evaluate CD155 expression in tumor tissues and explore its potential relationship with the anti-tumor activity and safety of TGI-5 injection. ● Explore the relationship between dose and PK exposure and effect (including efficacy and/or safety).

Start Date12 Jun 2025

Sponsor / Collaborator

Hefei TG ImmunoPharma Co., Ltd

NCT07376707

/ RecruitingPhase 1

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors

This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary antitumor activity of TGI-5 as monotherapy and in combination with Nivolumab in subjects with unresectable locally advanced/metastatic solid tumors.
The study consists of two parts: TGI-5 monotherapy (Phase 1a: including a dose escalation part and a dose expansion part), TGI-5 in combination with a fixed dose of Nivolumab (Phase 1b: including a dose escalation part and a dose expansion part).

Start Date12 Jun 2025

Sponsor / Collaborator

Hefei TG ImmunoPharma Co., Ltd

[+1]

NCT06374173

/ RecruitingPhase 1

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics, and Antitumor Activity of TGI-6 as Monotherapy in Subjects With Locally Advanced/Metastatic Solid Tumors

A Phase 1 Study to Evaluate TGI-6 in Subjects with Locally Advanced/Metastatic Solid Tumors

Start Date03 Jan 2024

Sponsor / Collaborator

Hefei TG ImmunoPharma Co., Ltd

100 Clinical Results associated with Hefei TG ImmunoPharma Co., Ltd

Login to view more data

0 Patents (Medical) associated with Hefei TG ImmunoPharma Co., Ltd

Login to view more data

100 Deals associated with Hefei TG ImmunoPharma Co., Ltd

Login to view more data

100 Translational Medicine associated with Hefei TG ImmunoPharma Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 17 Aug 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

13

4

Preclinical

Phase 1

3

9

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

TGI-6 ( CD3 x TAA )	Colorectal Cancer More	Phase 1
TGI-2 ( CD112R )	Advanced Malignant Solid Neoplasm More	Phase 1
TGI-5 ( CD112R )	Solid tumor More	IND Approval
TGI-14 ( CD3 )	Neoplasms More	Preclinical
TGI-17 ( IL2RA x PD-1 )	Neoplasms More	Preclinical